Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles: Therapeutics, Targets, and Development

A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development

Antonio Jimeno, Georg Feldmann, Ana Suárez-Gauthier, Zeshaan Rasheed, Anna Solomon, Gang-Ming Zou, Belen Rubio-Viqueira, Elena García-García, Fernando López-Ríos, William Matsui, Anirban Maitra and Manuel Hidalgo
Antonio Jimeno
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georg Feldmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Suárez-Gauthier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zeshaan Rasheed
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Solomon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gang-Ming Zou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Belen Rubio-Viqueira
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena García-García
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando López-Ríos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Matsui
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anirban Maitra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuel Hidalgo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-08-0924 Published February 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    After 4 wk of induction with gemcitabine, the cohort 2 showed a plateau in effect. After re-randomization, the group released from gemcitabine (3) rapidly regrew, as did the group receiving cyclopamine (5). The group that continued gemcitabine (4) remained in an activity plateau. Only the combination therapy group (6) showed incremental effect, and these tumors homogeneously regressed to 50% of the initial size after 4 wk. Bars, SD.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    A, immunohistochemical assessment of CD24, CD44, and ALDH by immunohistochemistry. CD44 presented a flat staining that was not different between groups. However, both CD24 and ALDH had a pattern consisting in inversely intense staining with tumor size, with maximal staining in gemcitabine-treated and gemcitabine + cyclopamine-treated groups. B, tumor growth, mouse nestin expression, cytoplasmic CD24, ALDH by reverse transcription-PCR and immunohistochemistry, and GLI1 mRNA expression. ALDH by immunohistochemistry was particularly differentiating as the low-level expression followed an all-or-nothing pattern. ALDH was only positive in 2% of the cells in the gemcitabine-treated groups. In the group where gemcitabine is ceased, the TSC markers (both CD24 and ALDH) decreased back to the levels of the untreated group, suggesting a repopulation of proliferating cells and a dilution of the TSC-enriching effect.

PreviousNext
Back to top
Molecular Cancer Therapeutics: 8 (2)
February 2009
Volume 8, Issue 2
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
Antonio Jimeno, Georg Feldmann, Ana Suárez-Gauthier, Zeshaan Rasheed, Anna Solomon, Gang-Ming Zou, Belen Rubio-Viqueira, Elena García-García, Fernando López-Ríos, William Matsui, Anirban Maitra and Manuel Hidalgo
Mol Cancer Ther February 1 2009 (8) (2) 310-314; DOI: 10.1158/1535-7163.MCT-08-0924

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development
Antonio Jimeno, Georg Feldmann, Ana Suárez-Gauthier, Zeshaan Rasheed, Anna Solomon, Gang-Ming Zou, Belen Rubio-Viqueira, Elena García-García, Fernando López-Ríos, William Matsui, Anirban Maitra and Manuel Hidalgo
Mol Cancer Ther February 1 2009 (8) (2) 310-314; DOI: 10.1158/1535-7163.MCT-08-0924
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results and Discussion
    • Disclosure of Potential Conflicts of Interest
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma
  • Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells
  • MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
Show more Research Articles: Therapeutics, Targets, and Development
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement